Document is current
Any future updates will be listed below
-
Authors
Rodriguez-Granrose, Daniel http://orcid.org/0000-0003-4350-9221
Zurawski, Jeff
Heaton, Will
Tandeski, Terry
Dulatov, Galina
Highsmith, Angelica Adrian
Conen, Mason
Clark, Garrett
Jones, Amanda
Loftus, Hannah
LeBaron, Cameron
Scull, Erin
Farhang, Niloo
Erickson, Isaac
Bingham, Justin
Decaria, Paula
Jones, Nephi
Foley, Kevin T.
Silverman, Lara
-
Funding
Funding for this research was provided by:
DiscGenics Inc.
National Science Foundation (1451511)
- License Information
-
More Information
Article History
Received: 2 April 2021
Accepted: 20 July 2021
First Online: 12 August 2021
Declarations
:
: This study was performed with oversight by a private Institutional Animal Care and Use Committee (IACUC) and adhered to US Good Laboratory Practice standards. DGx process development work is in support of attaining BLA clearance under a US FDA allowed IND (IND17490), all tissue has been fully consented and obtained by a federally accredited procurement agency adhering to FDA 21 CFR 1271 regulations regarding organ and tissue procurement.
: None.
: Daniel Rodriguez-Granrose, Jeff Zurawski, Will Heaton, Terry Tandeski, Galina Dulatov, Angelica Adrian Highsmith, Mason Conen, Garrett Clark, Amanda Jones, Hannah Loftus, Cameron LeBaron, Erin Scull, Niloo Farhang, Isaac Erickson, Justin Bingham, Kevin T Foley, and Lara Silverman own stock or stock options in DiscGenics. Kevin T Foley is on the board of DiscGenics. Paula Decaria and Nephi Jones own stock or stock options in Thermo Fisher Scientific.
